Ignite Creation Date:
2024-05-05 @ 12:10 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00263653
Status:
COMPLETED
Last Update Posted:
2016-09-21
First Post:
2005-12-08
Brief Title:
Safety Reactogenicity Immunogenicity Study to Evaluate a Booster Dose of GSK Biologicals Hib-MenC Given With Priorix in Toddlers 13-14 m Primed With 3 Doses of Hib and MenC-CRM197
Sponsor:
Organization:
GlaxoSmithKline
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
297
Enrollment Type:
ACTUAL
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| PHASE3 |
Observational Models:
Time Perspective List:
Who Masked List: